Table 3.
Uniquely detected proteins in subcutaneous abdominal fat (in at least 40% of patients).
| Protein ID | Protein Name | % of Patients | p-Value | Database | KEGG Pathway |
|---|---|---|---|---|---|
| P28330 | Long-chain specific acyl-CoA dehydrogenase, mitochondrial | 60% | 3.41 × 10−3 | KEGG | Fatty acid degradation, fatty acid metabolism, metabolic pathways, PPAR signaling pathway |
| Q96HY7 | Probable 2-oxoglutarate dehydrogenase E1 component DHKTD1, mitochondrial | 60% | 3.41 × 10−3 | KEGG | Lysine degradation, tryptophan metabolism, lipoic acid metabolism, metabolic pathways, biosynthesis of secondary metabolites, 2-oxocarboxylic acid metabolism |
| P04440 | HLA class II histocompatibility antigen, DP beta 1 chain | 60% | 3.41 × 10−3 | UNIPROT | Downstream TCR signaling, CD3 and TCR zeta chain phosphorylation, translocation of ZAP-70 to immunological synapse, generation of second messenger molecules, Presentation of MHC class II antigens |
| P47712 | Cytosolic phospholipase A2 | 50% | 9.82 × 10−3 | see 23 pathways in the link | https://www.genome.jp/dbget-bin/www_bget?hsa:5321 (accessed on 10 May 2024) |
| Q8IWW8 | Hydroxyacid-oxoacid transhydrogenase, mitochondrial | 50% | 9.82 × 10−3 | HMDB | Oncogenic action of D-2-hydroxyglutarate in hydroxygluaricaciduria, oncogenic action of L-2-hydroxyglutarate in hydroxygluaricaciduria |
| Q10713 | Mitochondrial-processing peptidase subunit alpha | 50% | 9.82 × 10−3 | PHAROS | Mitochondrial calcium ion transport, 3-phosphoinositide degradation, mitochondrial protein import, processing of SMDT1, protein localization, small molecule transport |
| Q6GTX8; Q6ISS4 | Leukocyte-associated immunoglobulin-like receptor 1 | 50% | 9.82 × 10−3 | PHAROS | Adaptive immune system (R-HSA-1280218), immune system (R-HSA-168256), immunoregulatory interactions between lymphoid and non-lymphoid cells (R-HSA-198933), innate immune system (R-HSA-168249), neutrophil degranulation (R-HSA-6798695) |
| Q13424 | Alpha-1-syntrophin | 50% | 9.82 × 10−3 | KEGG | TGF-beta signaling pathway, ECM-receptor interaction, Renin-angiotensin system, JAK-STAT signaling pathway |
| Q5TFE4 | 5-nucleotidase domain-containing protein 1 | 50% | 9.82 × 10−3 | Not found | |
| Q92552 | 28S ribosomal protein S27, mitochondrial | 50% | 9.82 × 10−3 | Mitochondrial translation | |
| Q96GG9 | DCN1-like protein 1 | 50% | 9.82 × 10−3 | Neddylation, post-translational protein modification | |
| Q14008 | Cytoskeleton-associated protein 5 | 40% | 2.53 × 10−2 | See super pathways and contained pathways in the link | https://www.genecards.org/cgi-bin/carddisp.pl?gene=CKAP5#pathways_interactions (accessed on 10 May 2024) |
| Q6L8Q7 | 2,5-phosphodiesterase 12 | 40% | 2.53 × 10−2 | PHAROS | Antiviral mechanism by IFN-stimulated genes, cytokine signaling in immune system, immune system, interferon signaling, OAS antiviral response |
| P10619 | Lysosomal protective protein | 40% | 2.53 × 10−2 | KEGG | Other glycan degradation, glycosaminoglycan degradation, SNARE interactions in vesicular transport, autophagy—animal, endocytosis |
| P27918 | Properdin | 40% | 2.53 × 10−2 | PHAROS | Complement cascade, immunoregulatory interactions between a lymphoid and a non-lymphoid cell, cell recruitment (pro-inflammatory response) |
| Q9BYT8 | Neurolysin, mitochondrial | 40% | 2.53 × 10−2 | Renin-angiotensin system | |
| O94925 | Glutaminase kidney isoform, mitochondrial | 40% | 2.53 × 10−2 | KEGG | Citrate cycle (TCA cycle), pyrimidine metabolism, alanine, aspartate and glutamate metabolism, arginine and proline metabolism, D-amino acid metabolism, nitrogen metabolism |
| P06454 | Prothymosin alpha | 40% | 2.53 × 10−2 | PHAROS | Validated targets of C-MYC transcriptional activation |